公开(公告)号：US20240270753A1

公开(公告)日：2024-08-15

申请号：US18560605

申请日：2022-03-30

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Bing ZHOU ,  Jia LI ,  Yubo ZHOU ,  Xiangbo YANG ,  Bo FENG ,  Yaxi YANG ,  Xiaobei HU

IPC: C07D491/107 ,  A61K31/497 ,  A61K31/5025 ,  C07D519/00

CPC classification number: C07D491/107 ,  A61K31/497 ,  A61K31/5025 ,  C07D519/00

Abstract: The present invention relates to a heterocyclic compound for inhibiting SHP2 activity that is represented by formula I, a preparation method therefor and use thereof. The compound of the present invention is effective in treating a disease or disorder or condition mediated by SHP2.

公开(公告)号：US20210371430A1

公开(公告)日：2021-12-02

申请号：US17289642

申请日：2019-10-08

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Bing ZHOU ,  Wei TANG ,  Xiangbo YANG ,  Huimin LU ,  Mengying GAO ,  Yaxi YANG ,  Huijin FENG

IPC: C07D513/04 ,  A61P37/06 ,  C07D413/14 ,  C07D413/12 ,  C07D487/04 ,  C07D401/14 ,  C07D401/12 ,  C07D417/14 ,  C07D417/12

Abstract: The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase.